ThinkGenetic, Inc. is a leading digital health company specializing in finding individuals at risk of rare genetic conditions. Leveraging sensitive algorithms and extensive expertise in rare diseases, ThinkGenetic offers validated digital solutions to detect patients for diagnosis, treatment, and clinical trials, while ensuring compliance with important PHI (Protected Health Information) regulations. The company serves clients in biopharma, research institutions, and advocacy organizations, empowering them to uncover at-risk patients and provide essential resources to support critical healthcare decisions using the power of AI technology.
Our history
2015
Founding Inspiration and Pioneering ThinkGenetic’s Vision
Inspired by a personal experience living with a genetic disease, co-founders Dave Jacob and Len Barker, uncovered an opportunity to help the genetic disease community. IBM extended an invitation for partners to propose a commercial application using the new Watson technology. Collaborating with Dawn Laney, a well-respected genetic counselor at Emory University, the three embarked on a venture to develop a pilot project. This successful pilot marked the genesis of ThinkGenetic and the company’s dedication to leveraging cutting-edge technology with clinical expertise to address the needs of individuals and families affected by genetic and rare diseases.
2016
Building a Foundation for Impact
Recognizing the full potential of this novel idea, ThinkGenetic was incorporated. That same year a beta version of a patient-focused application was released. This groundbreaking app was developed to offer invaluable assistance and trusted information to medical professionals and patients asking real-world questions about living with rare genetic diseases. By tapping into the vast expertise of genetic counselors, the tool amassed an extensive repository of content encompassing over 350 distinct conditions.
2017
Expanding to Meet Demand
As ThinkGenetic gained recognition, our client base and team expanded in tandem with the company’s success. This surge solidified ThinkGenetic’s position as a trusted resource for the genetic community and underscored the value of its solutions. Simultaneously, the company embarked on the development of SymptomMatcher – an innovative screening tool that harnessed curated content and intuitive computing. SymptomMatcher aimed to empower undiagnosed individuals by helping them recognize symptoms within themselves, thereby accelerating the path to a genetic diagnosis. During its initial phase, SymptomMatcher was offered as a complimentary resource on the ThinkGenetic website, delivering an immersive and multifaceted experience based on the clinical signs entered by users.
2018
Expanding Impact through Partnerships and Milestones
Continuing its trajectory of growth and recognition, ThinkGenetic forged partnerships with new clients and enabled a significant milestone—the successful publication of the first validation study. In addition, through strategic alliance, ThinkGenetic’s website and SymptomMatcher users were granted direct access to care services, elevating the overall experience and value offered by ThinkGenetic. ThinkGenetic was also named a PULSE@MassChallenge top digital health company.
2019
Forging Impactful Alliances
Following a year of extensive exploration and research, ThinkGenetic successfully established direct partnerships with prominent entities in biopharma as well as its first health system. These alliances opened doors to exciting prospects and allowed for exploration into the future applications of ThinkGenetic’s advanced knowledge and cutting-edge platforms. By joining forces, ThinkGenetic reinforced its dedication to real-world implementation and validation of its solutions, positioning the company as a valuable partner in the pursuit of improved healthcare outcomes and better patient experiences.
2020
Global Impact and Collaborative Success
In a momentous stride, ThinkGenetic SymptomMatcher achieved its official launch of a global pilot program. As part of this pioneering initiative, SymptomMatcher was seamlessly integrated as an embedded tool and quickly garnered attention and appreciation, prompting an expansion of the pilot to encompass additional regions globally. Through this extensive expansion, ThinkGenetic solidified its position as a trusted and invaluable partner in facilitating condition awareness campaigns on a global scale.
2021
Advancing Innovation and Receiving Recognition
With SympomMatcher firmly established as a solution, ThinkGenetic began expanding upon its goal of utilizing its algorithms for expanded use. The introduction of ThinkGenetic’s innovative solution for patient identification in electronic health records, FindEHR, sparked significant interest within the healthcare community, drawing attention from prominent entities in rare diseases. This interest culminated in a momentous achievement for ThinkGenetic, as the company was honored as the inaugural recipient of the prestigious Horizon Prize, Powered by MIT Solve. This achievement served as a testament to the company’s dedication to innovation and its unwavering pursuit of excellence in the pursuit of improved healthcare outcomes and patient well-being.
2022
Elevating Diagnostics through Strategic Collaboration
After successfully launching FindEHR pilots, ThinkGenetic announced a clinical partnership with Guardian Research Network (GRN) to facilitate the integration of ThinkGenetic’s advanced algorithms with millions of electronic health records. The transformative collaboration proved to be a game-changer. ThinkGenetic’s solutions attracted new and esteemed clients and underscored the immense value and relevance of ThinkGenetic’s platform within the pharmaceutical industry. By unlocking the potential of electronic health records ThinkGenetic forged partnerships with leading pharmaceutical entities. The company’s dedication to making a tangible difference in the lives of patients affected by rare diseases garnered widespread recognition, further fueling its momentum as a driving force in the field of digital health solutions.
2023
Advancing Precision Medicine: Introducing Validated Products, FindEHR, and FindSM
Building upon its successful research and development efforts, ThinkGenetic formally introduced two products, FindEHR and FindSM, to the market. These products marked a significant milestone for the company, representing the culmination of rigorous testing, validation, and refinement processes. With these validated products, ThinkGenetic continues to redefine the standards of precision medicine. The company’s dedication to driving positive change within the healthcare industry, coupled with its commitment to scientific excellence, has propelled ThinkGenetic forward as a transformative force shaping the future of digital health solutions for rare disease.
